3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Polycythemia Vera
4
Leukemia, Myeloid, Acute
4
Treatment-Refractory Solid Tumors
2
Meningioma
2
Squamous Cell Carcinoma of Head and Neck
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Leukemia, Myelomonocytic, Chronic
1
Head and Neck Neoplasms
1
Bone Marrow Neoplasms
1
Bites and Stings
1
Interventions
Azacitidine
25
venetoclax
19
Cyclophosphamide
17
fludarabine phosphate
14
Whole-Body Irradiation
13
Biopsy
13
fludarabine
12
Specimen Handling
12
Tacrolimus
11
Mycophenolic Acid
11
Decitabine
10
Stem Cell Transplantation
9
Peripheral Blood Stem Cell Transplantation
9
Injections
8
Cytarabine
8
Busulfan
8
decitabine and cedazuridine drug combination
7
Melphalan
7
X-Rays
5
Hematopoietic Stem Cell Transplantation
5
Cyclosporine
5
Sirolimus
4
ruxolitinib
3
olutasidenib
3
enasidenib
3
cedazuridine
3
Magnetic Resonance Spectroscopy
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelomonocytic, Chronic
×
Hydroxyurea
×
1 year
×
Clear all
NCT07033598
2026-03-05
PROSPERA
Theradex
Phase 2
Recruiting
66 enrolled